Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 injection plus bevacizumab + XELOX vs placebo plus bevacizumab + XELOX in first-line treatment of unresectable metastatic colorectal cancer
CTR20252219Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of QL1706 in colorectal adenocarcinoma, sponsored by Qilu Pharmaceutical. Started Aug 2025; status: active.
02
Drugs
QL1706
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on CTR20252219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252219.